David M Vossen1, Caroline V M Verhagen1, Marcel Verheij2, Lodewyk F A Wessels3, Conchita Vens4, Michiel W M van den Brekel5. 1. Division of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 2. Division of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. 3. Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of EEMCS, Delft University of Technology, Delft, The Netherlands. 4. Division of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: c.vens@nki.nl. 5. Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Institute of Phonetic Sciences, University of Amsterdam, Amsterdam, The Netherlands; Department of Oral and Maxillofacial Surgery, Academic Medical Center, Amsterdam, The Netherlands. Electronic address: m.vd.brekel@nki.nl.
Abstract
OBJECTIVE: Locally advanced oral squamous cell carcinoma (OSCC) shows lower locoregional control and disease specific survival rates than laryngeal and pharyngeal squamous cell carcinoma (L/P-SCC) after definitive chemoradiotherapy treatment. Despite clinical factors, this can point towards a different tumor biology that could impact chemoradiotherapy response rates. This prompted us to compare the mutational profiles of OSCC with L/P-SCC. METHODS: We performed target capture DNA sequencing on 111 HPV-negative HNSCC samples (NKI dataset), 55 oral and 56 laryngeal/pharyngeal, and identified somatic point mutations and copy number aberrations. We next expanded our analysis with 276 OSCC and 134 L/P-SCC sample data from The Cancer Genome Atlas (TCGA dataset). We focused our analyses on genes that are frequently mutated in HNSCC. RESULTS: The mutational profiles of OSCC and L/P-SCC showed many similarities. However, OSCC was significantly enriched for CASP8 (NKI: 15% vs 0%; TCGA: 17% vs 2%) and HRAS (TCGA: 10% vs 1%) mutations. LAMA2 (TCGA: 5% vs 19%) and NSD1 (TCGA: 7% vs 25%) mutations were enriched in L/P-SCC. Overall, we find that OSCC had fewer somatic point mutations and copy number aberrations than L/P-SCC. Interestingly, L/P-SCC scored higher in mutational and genomic scar signatures associated with homologous recombination DNA repair defects. CONCLUSION: Despite showing a similar mutational profile, our comparative genomic analysis revealed distinctive features in OSCC and L/P-SCC. Some of these genes and cellular processes are likely to affect the cellular response to radiation or cisplatin. Genomic characterizations may guide or enable personalized treatment in the future.
OBJECTIVE: Locally advanced oral squamous cell carcinoma (OSCC) shows lower locoregional control and disease specific survival rates than laryngeal and pharyngeal squamous cell carcinoma (L/P-SCC) after definitive chemoradiotherapy treatment. Despite clinical factors, this can point towards a different tumor biology that could impact chemoradiotherapy response rates. This prompted us to compare the mutational profiles of OSCC with L/P-SCC. METHODS: We performed target capture DNA sequencing on 111 HPV-negative HNSCC samples (NKI dataset), 55 oral and 56 laryngeal/pharyngeal, and identified somatic point mutations and copy number aberrations. We next expanded our analysis with 276 OSCC and 134 L/P-SCC sample data from The Cancer Genome Atlas (TCGA dataset). We focused our analyses on genes that are frequently mutated in HNSCC. RESULTS: The mutational profiles of OSCC and L/P-SCC showed many similarities. However, OSCC was significantly enriched for CASP8 (NKI: 15% vs 0%; TCGA: 17% vs 2%) and HRAS (TCGA: 10% vs 1%) mutations. LAMA2 (TCGA: 5% vs 19%) and NSD1 (TCGA: 7% vs 25%) mutations were enriched in L/P-SCC. Overall, we find that OSCC had fewer somatic point mutations and copy number aberrations than L/P-SCC. Interestingly, L/P-SCC scored higher in mutational and genomic scar signatures associated with homologous recombination DNA repair defects. CONCLUSION: Despite showing a similar mutational profile, our comparative genomic analysis revealed distinctive features in OSCC and L/P-SCC. Some of these genes and cellular processes are likely to affect the cellular response to radiation or cisplatin. Genomic characterizations may guide or enable personalized treatment in the future.
Authors: Alexander Y Deneka; Yasmine Baca; Ilya G Serebriiskii; Emmanuelle Nicolas; Mitchell I Parker; Theodore T Nguyen; Joanne Xiu; W Michael Korn; Michael J Demeure; Trisha Wise-Draper; Ammar Sukari; Barbara Burtness; Erica A Golemis Journal: Clin Cancer Res Date: 2022-05-02 Impact factor: 13.801
Authors: Marcin M Machnicki; Anna Rzepakowska; Joanna I Janowska; Monika Pepek; Alicja Krop; Katarzyna Pruszczyk; Piotr Stawinski; Malgorzata Rydzanicz; Jakub Grzybowski; Barbara Gornicka; Maciej Wnuk; Rafal Ploski; Ewa Osuch-Wojcikiewicz; Tomasz Stoklosa Journal: Front Oncol Date: 2022-05-19 Impact factor: 5.738
Authors: Paul B M Essers; Martijn van der Heijden; David Vossen; Reinout H de Roest; C René Leemans; Ruud H Brakenhoff; Michiel W M van den Brekel; Harry Bartelink; Marcel Verheij; Conchita Vens Journal: Int J Cancer Date: 2020-03-30 Impact factor: 7.396
Authors: Andrew P South; Nicoline Y den Breems; Tony Richa; Uche Nwagu; Tingting Zhan; Shiv Poojan; Ubaldo Martinez-Outschoorn; Jennifer M Johnson; Adam J Luginbuhl; Joseph M Curry Journal: Sci Rep Date: 2019-12-17 Impact factor: 4.379
Authors: R de Haan; E van Werkhoven; M M van den Heuvel; H M U Peulen; G S Sonke; P Elkhuizen; M W M van den Brekel; M E T Tesselaar; C Vens; J H M Schellens; B van Triest; M Verheij Journal: BMC Cancer Date: 2019-09-10 Impact factor: 4.430